[go: up one dir, main page]

AR110371A1 - FORMULATION OF PHARMACEUTICAL TABLETS - Google Patents

FORMULATION OF PHARMACEUTICAL TABLETS

Info

Publication number
AR110371A1
AR110371A1 ARP170103512A ARP170103512A AR110371A1 AR 110371 A1 AR110371 A1 AR 110371A1 AR P170103512 A ARP170103512 A AR P170103512A AR P170103512 A ARP170103512 A AR P170103512A AR 110371 A1 AR110371 A1 AR 110371A1
Authority
AR
Argentina
Prior art keywords
heart failure
formulation
pharmaceutical tablets
hfref
hfpef
Prior art date
Application number
ARP170103512A
Other languages
Spanish (es)
Inventor
Stroyer Anke Dr
Schwer Christine Dr
Pfeffer Michael Dr
Lobback Carmen Dr
Ide Katrin Dr
Serno Peter Dr
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AR110371A1 publication Critical patent/AR110371A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulación de comprimido farmacéutico que comprende 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridin-4-il]fenoxi}etil-L-alanil-L-alaninato (neladenoson bialanato) en la forma de una de sus sales, en donde libera el ingrediente activo rápidamente, y a procesos para su producción, al uso de este como un medicamento, y al uso de este para la profilaxis y/o tratamiento de trastornos cardiovasculares, por ejemplo insuficiencia cardíaca crónica agravada, insuficiencia cardíaca con fracción de eyección del ventrículo izquierdo reducida o conservada (HFrEF o HFpEF), angina pectoris y lesión isquémica durante un síndrome coronario agudo.Pharmaceutical tablet formulation comprising 2- {4- [2 - ({[2- (4-chlorophenyl) -1,3-thiazol-4-yl] methyl} sulfanyl) -3,5-dicyano-6- (pyrrolidin -1-yl) pyridin-4-yl] phenoxy} ethyl-L-alanyl-L-alaninate (neladenoson bialanate) in the form of one of its salts, where it releases the active ingredient quickly, and to processes for its production, by use of this as a medicine, and the use of this for the prophylaxis and / or treatment of cardiovascular disorders, for example aggravated chronic heart failure, heart failure with reduced or preserved left ventricular ejection fraction (HFrEF or HFpEF), angina pectoris and ischemic injury during an acute coronary syndrome.

ARP170103512A 2016-12-16 2017-12-14 FORMULATION OF PHARMACEUTICAL TABLETS AR110371A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16204750 2016-12-16

Publications (1)

Publication Number Publication Date
AR110371A1 true AR110371A1 (en) 2019-03-20

Family

ID=57614148

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103512A AR110371A1 (en) 2016-12-16 2017-12-14 FORMULATION OF PHARMACEUTICAL TABLETS

Country Status (4)

Country Link
AR (1) AR110371A1 (en)
TW (1) TW201836592A (en)
UY (1) UY37525A (en)
WO (1) WO2018108884A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807715B2 (en) 2006-06-09 2010-10-05 Ucb Pharma Gmbh Pharmaceutical compositions comprising fesoterodine
DE102009006602A1 (en) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs
US20180155336A1 (en) 2015-05-06 2018-06-07 Bayer Pharma Aktiengesellschaft Process for the preparation of 2-{4-[2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyan0-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}ethyl-l-alanyl-l-alaninate monohydrochloride

Also Published As

Publication number Publication date
WO2018108884A1 (en) 2018-06-21
UY37525A (en) 2018-06-29
TW201836592A (en) 2018-10-16

Similar Documents

Publication Publication Date Title
MX2019008127A (en) Pharmaceutical compositions comprising meloxicam.
CR20130649A (en) MODIFIED RELEASE OF 4-METHYL-3 - [[4- (3-PYRIDINYL) -2-PYRIMIDINYL] -AMINO] -N- [5- (4-METHYL-1H-IMIDAZOL-1-IL) -3- (TRIFLUORO -METIL) -PENYL] -BANZAMIDE SOLUBILIZED USING ORGANIC ACIDS
MX2021003230A (en) PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM.
MX2021013817A (en) NEW CRYSTALLINE FORMS OF N-(3-(2-(2-HYDROXYETOXY)-6-MORPHOLINOP IRIDIN-4-IL)-4-METHYLPHENYL)-2-(TRIFLUOROMETHYL)SONICOTINAMIDE AS RAF INHIBITORS FOR THE TREATMENT OF CANCER.
MX2017004053A (en) DEVICE AND METHOD FOR DISPENSING A PHARMACO.
MX2019013714A (en) TREATMENT METHODS.
MX2018005620A (en) COMPOSITIONS THAT INCLUDE A SPECIFIC DEMETILASE-1 INHIBITOR OF LISINA.
BR112018077457A2 (en) pharmaceutical composition to prevent or treat congenital hyperinsulinism and its method, hypoglycemia and its method, metabolic syndrome and its method and isolated peptide
CL2015000880A1 (en) Heterocyclic compounds derived from 4-pyrimidinone, hiv reverse transcriptase inhibitors; pharmaceutical composition; use in the prophylaxis or treatment of hiv infection or for the prophylaxis, treatment or delay of the onset of AIDS in a subject.
MX2017013797A (en) Janus kinase inhibitor.
CO2017005544A2 (en) Multilayer tablet containing light unstable drug
CR20170314A (en) FORMULATION OF GLARGINE / LIXISENATIDA INSULIN FIXED RELATIONSHIP
MX2016008429A (en) DERIVED FROM PIRANOCROMENIL PHENOL, AND PHARMACEUTICAL COMPOSITION TO TREAT A METABOLIC SYNDROME OR INFLAMMATORY DISEASE.
IN2014MU01042A (en)
CO2017008115A2 (en) (2s, 4r) -5- (5'-chloro-2'-fluorobiphenyl-4-yl) -4- (ethoxyoxallylamino) -2-hydroxymethyl-2-methylpentanoic acid
BR112017028137A2 (en) therapeutic agent for fibrosis
DK3827829T3 (en) PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE, CONTAINING A GPR119 LIGAND AS ACTIVE INGREDIENT
PT3544977T (en) A maleate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof for the treatment of herpes viruses
MX2019001225A (en) NITROGENOUS HETEROCYCLIC AROMATIC COMPOUND, METHOD OF PREPARATION OF THE SAME, PHARMACEUTICAL COMPOSITION OF THE SAME AND APPLICATION OF THE SAME.
AR110371A1 (en) FORMULATION OF PHARMACEUTICAL TABLETS
AR107935A1 (en) USE OF COMPOUND 6- (4- (2,3-DIMETHYLPHENOXY) PIPERIDIN-1-IL) METHYL) PYRIMIDINE-2,4 (1H, 3H) -DIONA OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME TO PREPARE A MEDICINAL, COMBINATION AND COMPOSITION PHARMACEUTICAL UNDERSTANDING SUCH COMPOUND
MA42039A (en) PROCESS FOR THE PREPARATION OF 2- {4- [2 - ({[2- (4-CHLOROPHENYL) -1,3-THIAZOL-4-YL] METHYL} SULFANYL) -3,5-DICYAN-6- (PYRROLIDIN -1-YL) PYRIDIN-4-YL] PHENOXY} ETHYL-L-ALANYL-L-ALANINATE
BR112017004694A2 (en) pharmaceutical compositions comprising alpelisibe
CO2018014217A2 (en) Pharmaceutical compositions comprising safinamide
CY1122979T1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FUNGIASIS

Legal Events

Date Code Title Description
FB Suspension of granting procedure